Fc-receptor-mediated clearance and nonspecific phagocytic clearance were assessed after the infusion of monomeric human IgG, heat-aggregated human IgG, and a monoclonal anti-mouse macrophage FcII receptor antibody (2.4G2) into normal mice. Each agent blocked Fc-receptor function in vivo, but 2.4G2 was much more potent per microgram than the other agents. Monomeric IgG in blocking doses did not affect other aspects of immune function. In contrast, aggregated IgG, and to a lesser extent, 2.4G2 reduced serum complement levels. In addition, these agents also caused moderate reductions in nonspecific phagocytic function. Monoclonal anti-mouse macrophage C3bi receptor antibody (Mac-1), another monoclonal antibody which binds to macrophage CR3 receptors without interfering with Fc-receptor function, also reduced serum complement and inhibited nonspecific phagocytic function. Complement depletion alone (produced by infusion of cobra venom factor) could not account for the observed changes in Fc receptor or nonspecific phagocytic function. We conclude that both monomeric IgG and anti-Fc-receptor antibodies can markedly inhibit Fc-receptor function in vivo; however, the pattern of physiologic changes produced by these agents differs.
R J Kurlander, J Hall
Title and authors | Publication | Year |
---|---|---|
Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery.
Zelepukin IV, Shevchenko KG, Deyev SM |
Nature Communications | 2024 |
Advancement of Computational Design Drug Delivery System in COVID-19: Current Updates and Future Crosstalk- A Critical Update
Mohiuddin A, Mondal S |
Infectious Disorders Drug Targets | 2023 |
Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches
A Hasan, E Al-Ozairi, Z Al-Baqsumi, R Ahmad, F Al-Mulla |
ImmunoTargets and Therapy | 2021 |
COVID-19: inflammatory responses, structure-based drug design and potential therapeutics
N Tripathi, N Tripathi, MK Goshisht |
Molecular Diversity | 2021 |
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
Y Fu, Y Cheng, Y Wu |
Virologica Sinica | 2020 |
SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions
P Asrani, I Hassan |
Molecular and Cellular Biochemistry | 2020 |
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
SP Arlauckas, CS Garris, RH Kohler, M Kitaoka, MF Cuccarese, KS Yang, MA Miller, JC Carlson, GJ Freeman, RM Anthony, R Weissleder, MJ Pittet |
Science Translational Medicine | 2017 |
A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects: Ter119 Fc DOMAIN IN MURINE ITP TREATMENT
X Yu, M Menard, G Seabright, M Crispin, AH Lazarus |
Transfusion | 2015 |
FCGR2A rs1801274 polymorphism is associated with risk of childhood-onset idiopathic (immune) thrombocytopenic purpura: Evidence from a meta-analysis
D Wang, SL Hu, XL Cheng, JY Yang |
Thrombosis Research | 2014 |
FcγRIIa and FcγRIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome
A Papagianni, M Economou, A Tragiannidis, E Karatza, F Samarah, N Gombakis, F Athanassiadou-Piperopoulou, N Vavatsi–Christaki, M Athanassiou-Metaxa |
Blood Coagulation & Fibrinolysis | 2013 |
ANTI-MORPHINE ANTIBODY CONTRIBUTES TO THE DEVELOPMENT OF MORPHINE TOLERANCE IN RATS
H Kim, S Oh, B Sung, Y Tian, L Yang, S Wang, J Mao |
Neuroscience Letters | 2010 |
Intravenous immunoglobulin products: an update on their mechanisms of action
JW Semple, AR Crow, AH Lazarus, J Freedman, MB Garvey |
ISBT Science Series | 2008 |
The Mechanisms of Action of Intravenous Immunoglobulin and Polyclonal Anti-D Immunoglobulin in the Amelioration of Immune Thrombocytopenic Purpura: What Do We Really Know?
AR Crow, AH Lazarus |
Transfusion Medicine Reviews | 2008 |
Immunotherapy of chronic inflammatory demyelinating polyradiculoneuropathy
F Eftimov, IN Schaik |
Expert Opinion on Biological Therapy | 2008 |
BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer
LL pottier, B Bendaoud, M Dueymes, C Daridon, P Youinou, Y Shoenfeld, J Pers |
Journal of Clinical Immunology | 2007 |
Combination regimen of methylprednisolone, IV immunoglobulin, and plasmapheresis early in the treatment of acute disseminated encephalomyelitis
RP Lu, G Keilson |
Journal of Clinical Apheresis | 2006 |
Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia
AR Crow, S Song, V Siragam, AH Lazarus |
Pediatric Blood & Cancer | 2006 |
Facing the Enigma of Immunomodulatory Effects of Intravenous Immunoglobulin
T Sapir, Y Shoenfeld |
Clinical Reviews in Allergy & Immunology | 2005 |
The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile
MC Dalakas |
Pharmacology & Therapeutics | 2004 |
Effets immunomodulateurs des immunoglobulines intraveineuses
P Guilpain, Y Chanseaud, MC Tamby, C Larroche, L Guillevin, SV Kaveri, MD Kazatchkine, L Mouthon |
La Presse Médicale | 2004 |
Role of Fc?? Receptors in the Pathogenesis and Treatment of Idiopathic Thrombocytopenic Purpura
AR Crow, AH Lazarus |
Journal of Pediatric Hematology/Oncology | 2003 |
Mechanism of action of IVIG and anti-D in ITP
AH Lazarus, AR Crow |
Transfusion and Apheresis Science | 2003 |
Mechanism of action of IVIG in ITP
AH Lazarus |
Vox Sanguinis | 2002 |
Mechanisms of Intravenous Immunoglobulin Action in the Treatment of Autoimmune Disorders:
C Larroche, Y Chanseaud, P Garciadelapenalefebvre, L Mouthon |
BioDrugs | 2002 |
Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia
JL Teeling, T Jansen-Hendriks, TW Kuijpers, M de Haas, JG van de Winkel, CE Hack, WK Bleeker |
Blood | 2001 |
Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain
JL Arruda, S Sweitzer, MD Rutkowski, JA DeLeo |
Brain Research | 2000 |
Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines
MC Dalakas |
Muscle & Nerve | 1999 |
Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis
S Pradhan, RP Gupta, S Shashank, N Pandey |
Journal of the Neurological Sciences | 1999 |
Intravenous immunoglobulin and Anti-D in Idiopathic Thrombocytopenic Purpura (ITP): Mechanisms of Action
AH Lazarus, J Freedman, JW Semple |
Transfusion Science | 1998 |
Intravenous Immunoglobulin G and Anti-D as Therapeutic Interventions in Immune Thrombocytopenic Purpura
V Blanchette, M Carcao |
Transfusion Science | 1998 |
Characterization of anti-mouse FcγRII single-chain Fv fragments derived from human phage display libraries
AM McCall, AR Amoroso, C Sautès, JD Marks, LM Weiner |
Immunotechnology | 1998 |
Fc receptors in liver sinusoidal endothelial cells in NZB/W F1 lupus mice: A histological analysis using soluble immunoglobulin G–immune complexes and a monoclonal antibody (2.4G2)
SS Ahmed, H Muro, M Nishimura, I Kosugi, Y Tsutsui, H Shirasawa |
Hepatology | 1995 |
Intravenous gammaglobulin, 2: pharmacology, clinical uses and mechanisms of action
RI Schiff |
Pediatric Allergy and Immunology | 1994 |
Immunotherapy in Rheumatoid Arthritis: A Review
C Vitali, MS Bombardieri |
The International Journal of Artificial Organs | 1993 |
Intravenous immunoglobulin induces interferon-? and interleukin-6in vivo
ZD Ling, E Yeoh, BT Webb, K Farrell, J Doucette, DS Matheson |
Journal of Clinical Immunology | 1993 |
High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis
B Tumiati, P Casoli, M Veneziani, G Rinaldi |
Arthritis & Rheumatism | 1992 |
Proposed mechanisms of action of intravenous IgG (IVIG) in autoimmune diseases
TW Jungi, UE Nydegger |
Transfusion Science | 1992 |
Elimination of soluble123I-labeled aggregates of IgG in patients with systemic lupus erythematosus. Effect of serum IgG and numbers of erythrocyte complement receptor type 1
C Halma, MR Daha, JH Evers-Schouten, LA van Es, FC Breedveld, D Blok, J Hermans, EK Pauwels |
Arthritis & Rheumatism | 1991 |
Monomeric IgG2a promotes maturation of bone-marrow macrophages and expression of the mannose receptor
S Schreiber, JS Blum, WF Stenson, RP MacDermott, PD Stahl, SL Teitelbaum, SL Perkins |
Proceedings of the National Academy of Sciences | 1991 |
Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis
ED Silverman, RM Laxer, M Greenwald, E Gelfand, A Shore, LD Stein, CM Roifman |
Arthritis & Rheumatism | 1990 |
Cellular and Molecular Mechanisms of Inflammation
JA Odin, CJ Painter, JC Unkeless |
Cellular and Molecular Mechanisms of Inflammation | 1990 |
Use of Intravenous Gammaglobulin as an Immune Replacement and an Immune Suppressant
LK Boshkov, JG Kelton |
Transfusion Medicine Reviews | 1989 |
Murine natural killer cells express functional Fc gamma receptor II encoded by the Fc gamma R alpha gene
B Perussia, MM Tutt, WQ Qiu, WA Kuziel, PW Tucker, G Trinchieri, M Bennett, JV Ravetch, V Kumar |
Journal of Experimental Medicine | 1989 |
Fcγ Receptor Recognition of IgG Ligand by Human Monocytes and Macrophages
MD Rossman, E Chen, P Chien, M Rottem, A Cprek, AD Schreiber |
American journal of respiratory cell and molecular biology | 1989 |
Immune adherence and the processing of soluble complement-fixing antibody/DNA immune complexes in mice
JC Edberg, L Tosic, RP Taylor |
Clinical Immunology and Immunopathology | 1989 |
Perspectives in Antiinfective Therapy
GG Jackson, HD Schlumberger, HJ Zeiler |
1989 | |
Biochemistry and safety of native intravenous gammaglobulin (IGIV, pH 4.25)
RS Schwartz |
Journal of Clinical Apheresis | 1988 |
Immunotherapy of infectious diseases: past, present and future
JE Pennington |
Transactions of the American Clinical and Climatological Association | 1988 |
A new intravenous immunoglobulin in adult and childhood idiopathic thrombocytopenic purpura: a review
RH Rousell |
Journal of Infection | 1987 |
Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25
RS Schwartz |
The American Journal of Medicine | 1987 |
In Vivo Administration of Antibodies Against Type I Collagen in Rat: The Specific Accumulation in Spleen
GL Idelson, VR Muzykantov, EE Chekneva, AA Shnyra, BV Shekhonin, SP Domogatsky |
Collagen and Related Research | 1987 |
Gammaglobulin for intravenous use induces an Fc γ receptor-specific decrement in phagocytosis by blood monocytes
JE Salmon, S Kapur, RP Kimberly |
Clinical Immunology and Immunopathology | 1987 |